Cryo-Cell International (NYSEAMERICAN:CCEL) Shares Pass Above Two Hundred Day Moving Average – Here’s What Happened

Shares of Cryo-Cell International, Inc. (NYSEAMERICAN:CCEL) crossed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $0.00 and traded as high as $6.36. Cryo-Cell International shares last traded at $6.33, with a volume of 5,900 shares trading hands.

Wall Street Analysts Forecast Growth

Separately, Maxim Group reduced their price target on shares of Cryo-Cell International from $9.00 to $8.50 and set a “buy” rating on the stock in a research report on Tuesday, March 4th.

Cryo-Cell International Price Performance

The company has a market cap of $51.02 million, a P/E ratio of -5.97 and a beta of 0.53.

Cryo-Cell International Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, February 28th. Investors of record on Friday, February 14th were given a dividend of $0.25 per share. The ex-dividend date was Friday, February 14th. This represents a $1.00 dividend on an annualized basis and a yield of 15.80%. Cryo-Cell International’s dividend payout ratio is currently -94.34%.

Institutional Trading of Cryo-Cell International

A number of large investors have recently modified their holdings of CCEL. Geode Capital Management LLC increased its position in Cryo-Cell International by 68.5% in the 3rd quarter. Geode Capital Management LLC now owns 39,860 shares of the company’s stock valued at $254,000 after acquiring an additional 16,203 shares during the period. Heron Bay Capital Management acquired a new position in shares of Cryo-Cell International during the fourth quarter valued at $235,000. Rowlandmiller & PARTNERS.ADV bought a new stake in shares of Cryo-Cell International during the fourth quarter valued at about $107,000. Northern Trust Corp lifted its holdings in Cryo-Cell International by 78.2% in the fourth quarter. Northern Trust Corp now owns 38,902 shares of the company’s stock worth $288,000 after purchasing an additional 17,066 shares during the period. Finally, Topline Capital Management LLC bought a new position in Cryo-Cell International in the 4th quarter valued at about $354,000. Institutional investors and hedge funds own 10.44% of the company’s stock.

Cryo-Cell International Company Profile

Cryo-Cell International, Inc engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, auto-immune diseases, multiple sclerosis, Alzheimer's disease, Parkinson's diseases.